HEALTH TECHNOLOGY

Carilion Clinic and TytoCare Come Together for the Expansion of Telehealth Offerings

Tyto Care | June 09, 2022

Carilion Clinic


The healthcare industry’s first AI-powered modular device and examination offering, TytoCare has announced a partnership with Carilion Clinic, a premier not-for-profit organization focused on healthcare. Following the partnership, TytoCare will be integrated into Carilion’s virtual care solutions and will enhance the platform’s capabilities to provide virtual diagnosis and treatment and in-depth physical examinations in a virtual visit.

"We're thrilled to partner with TytoCare, an innovative telehealth solution that provides our physicians with the clinical data crucial to diagnosing and treating patients remotely. We're excited to bring these telehealth capabilities to rural communities that have historically been unable to use this new standard of healthcare. TytoCare's technology is intuitive and easy-to-use for patients and providers and supplies our patients with the convenient, quality care they deserve."

Stephen A. Morgan, M.D., Carilion Senior Vice President and Chief Medical Information Officer

Rural communities make up over two thirds of those suffering from a shortage of primary care medical professionals in the U.S. and Carilion is providing care for over 1 million people in Virginia, most of them in rural communities. In addition, TytoCare’s hand-held examination kit is cleared by the FDA and enables users to conduct an in-depth physical examination of the skin, heart, throat, ears, abdomen, and lungs. 

"We're excited to work with Carilion to enhance the quality and scope of telehealth visits for both patients and their physicians through our market-leading solution. As health systems reimagine what primary care looks like in 2022, they quickly understand that more virtual-first options benefit the entire health ecosystem and can be used to increase access to first-rate healthcare regardless of geographic region. TytoCare's remote physical examinations ensure that virtual-first programs deliver thorough, quality care to patients, no matter where they live."  

Dedi Gilad, CEO and Co-Founder of TytoCare
 

Spotlight

When providers find accurate, usable data within their EHR system, it increases efficiency and provides a comprehensive picture of patients' health. But unfortunately, the opposite is true as well. That is why, as this executive summary shows, ensuring EHR data quality is vital. Causes of missing and incorrect data, The costs to both providers and patients, The benefit of an expert third-party manual discrete clinical abstraction partner.

Spotlight

When providers find accurate, usable data within their EHR system, it increases efficiency and provides a comprehensive picture of patients' health. But unfortunately, the opposite is true as well. That is why, as this executive summary shows, ensuring EHR data quality is vital. Causes of missing and incorrect data, The costs to both providers and patients, The benefit of an expert third-party manual discrete clinical abstraction partner.

Related News

HEALTH TECHNOLOGY

Performant Capital Creates Platform Delivering Managed Technology Services and Revenue Cycle Management to the Healthcare Industry

Performant Capital | August 01, 2022

Performant Capital announced that it has formed Provider Technology, LLC through the acquisitions of DavLong Business Solutions LLC and its affiliate Administrative Advantage LLC and On Demand Solutions Inc. Provider Technology is a leading technology provider of outsourced software and IT services, revenue cycle management (“RCM”) and back-office business support primarily to physician practices and health systems. The businesses will continue to operate independently under their respective brands but share best practices across all functional areas. Performant, investing out of Fund I, closed the DBS and ODS transactions simultaneously in June. The Private Credit business within Goldman Sachs Asset Management provided first lien debt and an equity co-investment to support the acquisitions. “The team at Goldman Sachs has been invaluable as we executed this platform investment. We look forward to meaningfully accelerating the growth of the business given the scale enabled by Goldman’s partnership.” Mike Ciaglia, Partner at Performant Founded in 1983 and headquartered in Savannah, GA, DBS provides turnkey IT solutions for physician practices by fully hosting, maintaining, and supporting all software needs for the medical office, from cloud hosting to cybersecurity. DBS combines its proprietary suite of software offerings with leading third-party solutions to provide medical practices with a fully integrated electronic health record and practice management system from a single vendor. In addition to its best-in-class software offering, DBS also provides complete RCM services designed to manage and optimize the entire collections process for practices. Across both primary functional areas, the company leverages technology, analytics, and the expertise of its skilled teams to improve operational and financial performance for customers. Founded in 2007 and headquartered in Boise, ID, ODS provides practice management software, RCM, staffing support and business advisory services to healthcare service providers and organizations. Its solutions improve business operational efficiency, reduce administrative costs, and assure managerial control so clients can stay focused on providing quality patient care. The combination of DBS, AA, and ODS creates a national back-office and healthcare technology platform servicing more than 3,000 medical providers across the U.S and across medical specialties – developing best-in-class offerings and technology for specific specialties, such as Ophthalmology, EMS and Hospitalist providers. “These businesses are highly complementary acquisitions that together provide enhanced technology capabilities and support services with broader geographic presence to better meet the needs of clients and improve their financial outcomes,” said Chris McLaughlin, Partner at Performant Capital. “Both businesses have a reputation of providing superior customer support as value-added partners to physicians and health organizations. Customers value our company as more than just a service provider, but extensions of their core teams. With an expanded presence and enhanced capabilities to drive further value for clients, we’re excited about the future of the combined business under Provider Technology.” Provider Technology continues to look for best-in-class revenue cycle management and managed service provider software businesses to healthcare customers that would expand its geographic footprint and service capabilities. If you have an opportunity that might be an add-on acquisition candidate for Provider Technology, please contact Mike Ciaglia. About Performant Capital Performant Capital is a Chicago-based, lower middle market private equity firm focused on investments in technology-driven companies. Performant acquires businesses across SaaS, technology-enabled services, and data intelligence products and services. With over 50 years of collective investing and operating experience in these sectors, Performant’s principals seek opportunities where its depth of investing, operating expertise, and partner network can materially impact performance. More information on Performant Capital can be found at www.performantcapital.com. About Goldman Sachs Asset Management Private Credit Bringing together traditional and alternative investments, Goldman Sachs Asset Management provides clients around the world with a dedicated partnership and focus on long-term performance. As the primary investing area within Goldman Sachs it delivers investment and advisory services for the world’s leading institutions, financial advisors and individuals, drawing from its deeply connected global network and tailored expert insights, across every region and market—overseeing more than $2 trillion in assets under supervision worldwide as of March 31, 2022. Driven by a passion for its clients’ performance, it seeks to build long-term relationships based on conviction, sustainable outcomes, and shared success over time. Goldman Sachs Asset Management invests in the full spectrum of alternatives, including private equity, growth equity, private credit, real estate and infrastructure. Established in 1996, the Private Credit business within Goldman Sachs Asset Management is one of the world’s largest private credit investors with over $90 billion in assets across direct lending, mezzanine debt, hybrid capital and asset-based lending strategies. Its deep industry and product knowledge, extensive relationships and global footprint position it to deliver scaled outcomes with speed and certainty, supporting companies from the lower middle market to large cap in size.

Read More

HEALTH TECHNOLOGY

Viveon Health Acquisition Corp. Announces Filing of Registration Statement on Form S-4 in Connection with Suneva Medical

Viveon Health Acquisition Corp. | July 16, 2022

Viveon Health Acquisition Corp. a special purpose acquisition company, and Suneva Medical, Inc. an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, announced that VHAQ filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on July 13, 2022. The Registration Statement, contains a preliminary proxy statement/prospectus in connection with the previously announced business combination between VHAQ and Suneva. While the information within the Registration Statement is subject to change, it provides important information about Suneva Medical and VHAQ, as well as the proposed business combination. On January 12, 2022, VHAQ entered into a merger agreement with Suneva. The combined company is expected to be listed on the NYSE American upon completion of the transaction, which is expected to occur in the second half of 2022, subject to approval by VHAQ’s shareholders, the Registration Statement being declared effective by the SEC, and other customary closing conditions. Included in the Registration Statement are Suneva’s financial results for 2021 and for the first quarter of 2022. Overall, Suneva delivered strong revenue growth in 2021 and generated $29.5 million of net sales and $6.3 million in Q1 of 2022. Suneva’s full financial results and related disclosures can be found in the Registration Statement. About Suneva Medical, Inc. Suneva Medical, Inc., headquartered in San Diego, CA, is a leader in regenerative aesthetics. It is focused on developing, manufacturing and commercializing branded products for providers and their patients. Suneva offers a portfolio of products to address the impact of the aging process to deliver solutions that leverage the body’s own restorative capacity. The product portfolio is composed of several “only” and “first to market” solutions with both FDA PMA approval and 510(k) clearance. About Viveon Health Acquisition Corp. Viveon Health Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Read More

HEALTH TECHNOLOGY

Medical Device Innovation Consortium Launches Initiative to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics

MDIC | August 23, 2022

The Medical Device Innovation Consortium formally launched its Somatic Reference Samples Initiative with a pilot project to improve the validation and regulatory review process for cancer diagnostics based on next generation sequencing. MDIC will lead a collaboration with the U.S. Food and Drug Administration the National Institute of Standards and Technology, National Institutes of Health and industry stakeholders to manufacture, validate, and distribute SRSs to simplify and support validation of NGS-based cancer diagnostics. The initiative also includes the goal to create a publicly available global genomic data resource library of datasets with the potential to be used by sponsors and regulators. “NGS is a powerful technology enabling breakthroughs in diagnostics and ultimately therapeutics. These diagnostic tests need to be validated for accurate clinical use, and reference samples are essential to the validation process. But well-characterized and widely accepted reference materials do not exist for NGS-based diagnostics, complicating the development and validation process. Through the MDIC SRS Initiative, we are developing reference samples and data sets that can be used globally by test developers and regulators to bring more consistency to NGS-based cancer diagnostic development, increasing the confidence and accuracy of these tests, which will ultimately lead to more accuracy in diagnosis and treatment for patients.” Andrew Fish, President and CEO, MDIC “There is a need for appropriately consented, highly characterized, and broadly available reference materials that may improve the accuracy, reliability, and transparency of NGS-based oncology tests and support the generation of validation data for use in regulatory submissions. The reference samples and datasets being created by the MDIC Somatic Reference Samples Initiative can help fulfill this need,” said Wendy Rubinstein, MD, PhD, Director, Personalized Medicine, Center for Devices and Radiological Health, U.S. Food and Drug Administration. Horizon Discovery, a PerkinElmer company, is conducting the development and manufacture of these reference samples. The goal of this pilot project is to individually engineer 10 gene variants clinically associated with cancer into a highly characterized human cell line – GM24385 using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology resulting in ten edited human cell lines, each containing one gene variant clinically associated with one or more specific cancers. The cell lines, containing confirmed sequences, will be combined and available in FFPE format. The fully characterized reference samples will be commercially available to the end users from Horizon and the characterization data will be accessible through public databases, including precisionFDA, an FDA-sponsored site for data information, sequencing, and bioinformatics. NIST’s involvement in this work is to foster understanding.* “As our collaboration validates the MDIC SRS samples, we will also learn and build best practices to improve the efficiency and sustainability of reference sample validation and dataset generation in general. This project is a major step in the development and optimization of new sequencing technologies and the translation of DNA sequencing to clinical applications for diagnosing and treating cancer,” said Justin Zook, PhD, Co-Leader, Biomarker and Genomic Sciences Group, National Institute of Standards and Technology. MDIC’s SRS project began as a working group in 2018, representing more than forty stakeholders with a mission to address the gap in reference material for NGS-based diagnostic tests. The initial output of this working group, MDIC’s SRS Landscape Analysis, published in 2019, was a comprehensive catalog of existing clinically relevant cancer variants and available reference samples. Based on the unmet needs discovered through the SRS Landscape Analysis, the SRS Initiative has prioritized a subset of ten variants to be engineered into reference samples for the pilot project. In addition to the utility of these samples in development, validation, and regulatory review, these samples potentially have value in reimbursement decisions, post-market monitoring and informing the path forward for addition SRS. The work in the SRS Initiative is funded in part by the Gordon and Betty Moore Foundation the National Philanthropic Trust, Illumina, and Quidel. Affiliation with a commercial product does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose. About MDIC Founded in 2012, the Medical Device Innovation Consortium is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to transform health care into human care. Collaborating with our partners to advance science, we enable transformational medical technology to shape the world we want to live in and make that world possible by shortening the path from innovation to safety to access.

Read More